$30 Million

Immuneering Corporation

Underwritten Offering

Active Bookrunner, April 2023

Immuneering Corporation
Registered Direct Offering

Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing medicines for broad populations of cancer patients. The Company’s initial aim is to develop a universal-RAS therapy, an approach designed to include patients with solid tumors driven by any mutation in KRAS, NRAS or HRAS. Lead product candidate, IMM-1-104, a highly selective dual-MEK inhibitor, aims to achieve pan-KRAS/NRAS activity that selectively impacts cancer cells to a greater extent than healthy cells.

More Like This

Jun 2023

Acquired by MGP Ingredients, Inc

Exclusive Financial Advisor

View Details >
Jun 2023

Acquired by Bell (NYSE: BCE)

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >